GSK is increasingly confident that its anti-BCMA drug Blenrep could be returned to the US market, after revealing data from ...
Finally, for its ASCO ‘Super Sunday’ hat trick, AZ and Daiichi Sankyo reported results from the DESTINY-Breast06 trial, which ...
Share in GSK fell around 9% this morning after a judge in a Delaware court gave the green light for tens of thousands of lawsuits claiming harm by gastrointestinal drug Zantac to proceed to trial.